BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel...
Gene therapy MMA-101 has obtained both orphan drug designation and rare pediatric disease designation from the FDA RESEARCH TRIANGLE PARK,...
A pioneering researcher, Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapy Dr....
Proven Track Record of Technical Expertise Supporting Customers’ Product Sterility Requirements WINDSOR, Conn., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Scapa...
SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to...
NEWARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Teneobio Inc., a clinical stage biotech company focused on discovery and development...
Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients HOUSTON, Nov....
BOSTON and LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced...
Pivotal Trial Expected to be Initiated During 1Q21 HOUSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage...
WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing...
LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully...
Begins Enrollment in the First of Four Upcoming Late-Stage Trials in the U.S. Announces MIRA-1 Phase 2b Study Accepted for...
MALVERN, Pa., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute...
New Findings Show UroLift System Same-Day Outpatient Procedure Demonstrates Symptom Improvement for Benign Prostatic Hyperplasia WAYNE, Pa., Nov. 19, 2020...
52-week Phase 2 MERIDIAN study to evaluate pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with ALS WALTHAM, Mass....
- Company completes production of 1,200 FDA-cleared WellnessPro+ devices - Inventory build completed ahead of on-boarding new medical practitioners and...
‒ Completed Enrollment in Phase 2 Clinical Trial of EB613, Positioned as the First Potential Oral Bone Building Product to...
JANUARY – SEPTEMBER 2020 Net sales amounted to MSEK 0.0 (0.0) Operating expenses amounted to MSEK -19.8 (-22.9) Profit/loss before...
BRISBANE, Australia and EAGAN, Minn., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Anteris Technologies Ltd (ASX:AVR) (Anteris or the Company), a...
Results from first 13 patients in Roll-In Cohort showed over 90% reduction in mean frequency of therapeutic paracentesis versus baseline...